Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Communication To Shareholders - Dividend For FY 2021-22 - Intimation On Tax Deduction At Source (TDS) /Withholding Tax On Dividend

 Pursuant to the changes introduced by the Finance Act, 2020, Dividend Distribution Tax has been abolished with effect from 01 April 2020 and the Dividend Income is taxable in the hands of the Shareholders. In this regard, please find enclosed herewith an email communication which has been sent to all the shareholders having their email ID''s registered with the Company / Registrar & Transfer Agent / Depositories explaining the process and documentation required for claiming tax exemption/withholding tax on dividend to the Shareholders at prescribed rates. The above information shall be made available on the website of the Company at www.tatvachintan.com. You are requested to take the same on your records.
09-08-2022
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

 Pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Monitoring agency report of the Company for the quarter ended 30 June 2022, issued by ICICI Bank Limited, appointed to monitor the utilization of proceeds of an Initial Public Offering ('IPO') of the Company. The above information shall be made available on the website of the Company at www.tatvachintan.com. Kindly take the above information on your record.
06-08-2022
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Statement Of Deviation / Variation In Utilization Of Funds Raised Through IPO

 Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended 30 June 2022 in the prescribed format. The same will be filed in XBRL mode separately. We confirm that, as at 30 June 2022, there has not been any deviation(s) or variation(s) in the utilization of net proceeds of IPO as mentioned in the objects stated in the Prospectus dated 22 July 2021. Report issued by Monitoring agency report is being separately filed with the exchange. The above information shall be made available on the website of the Company at www.tatvachintan.com. Kindly take the above information on your record.
06-08-2022
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 25 July 2022 post announcement of financial results of the Company for the quarter ended 30 June 2022. The above information shall be made available on Company's website of at www.tatvachintan.com. This is for your information and records.
29-07-2022
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
28-07-2022
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are enclosing herewith copies of newspaper publication of extract of financial results of the Company for the quarter ended 30 June 2022, published in Financial Express (English edition) and Vadodara Samachar (Gujarati edition) on 26 July 2022. The above information shall be made available on the website of the Company at www.tatvachintan.com. Kindly take the same on record and disseminate to the public at large.
26-07-2022

Results Earnings Call for Q1FY23 of Tatva Chintan Pharma Chem

 Conference Call with Tatva Chintan Pharma Chem Ltd. Management and Analysts on Q1FY23 Performance and Outlook. Listen to the full earnings transcript.
26-07-2022
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Earnings Call Recording

 Pursuant to Regulation 46(2)(oa) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we hereby inform the exchanges that the recording of the Earnings Call held on Monday, 25 July 2022 at 05:00 pm IST is available on the website of the Company. The recording can be accessed from the following link: https://www.tatvachintan.com/wp-content/uploads/2022/07/Recording-2022-23-Q1.mp3 The above information is available on the website of the Company at www.tatvachintan.com. Kindly take above intimation on your record and oblige.
25-07-2022
Bigul

Q1FY23 Quarterly Result Announced for Tatva Chintan Pharma Chem Ltd.

 Tatva Chintan Pharma Chem Announced Q1FY23 results: Consolidated (YoY Q1FY23 compared with Q1FY22): Revenue from Operations for the quarter was Rs 884 million, declined by 17% EBITDA (excluding other income) for the quarter was Rs 152 million, declined by 42% EBIDTA Margin for the quarter was at 17% vs 25% in Q1FY22 Net Profit for the quarter was Rs 98 million declined by 58% Net Profit Margin for the quarter was at 11% vs 22% in Q1FY22 Basic and Diluted EPS for the quarter was Rs 4.42 per share vs Rs 11.5 in Q1FY22 Commenting on Q1FY23 Results, Mr. Chintan Shah, Managing Director, said, "on a full year basis FY22, the total revenue was Rs 4,336 million, out of which SDA contributed Rs 2,248 million. The other three product categories viz. PTC, ES and PASC together contributed Rs 2,058 million for the whole year, so on an average the quarterly sales of these three categories put together was at Rs 515 million against this during Q1FY23 we have achieved revenue of Rs 818 million in these three product categories showing a growth of nearly 60% which clearly reflects the growth potential of PTC, ES and PASC." Result PDF
25-07-2022
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Press Release on financial results of the Company for the quarter ended 30 June 2022. The above information shall be made available on the website of the Company at www.tatvachintan.com. This is for your information and records.
25-07-2022
Next Page
Close

Let's Open Free Demat Account